hotspot -WSS

hotspot

author：focus 2025-09-03 09:35:40 - browse：5386

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： CDC panel: People 65 and older should get a Covid spring booster shot

focus

WSS

Medicare Advantage isn’t working — for anyone

Ohio train derailment: Experts on toxic chemical risks

Ohio train derailment: Experts on toxic chemical risks

Are embryos people? Reproductive medicine's future depends on the answer

Megan Rapinoe shares emotional post following US Women's World Cup exit

Pfizer is about to make a big push in cancer. Will investors listen?

focus

hotspot

Wikipedia

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Study fuels hope CAR

Continuity nursing helped my family in our darkest PICU moments

Maui wildfire now ranks as the fifth

Moonlake's readout produced a cash windfall. Risks remain

Megan Rapinoe shares emotional post following US Women's World Cup exit

Hollywood unions extend contract negotiations for actors

Biogen’s boardroom scandal saddles CEO with first crisis

hotspot

Health AI: on the border between health care and tech

Change Healthcare cyberattack shows risk of industry consolidation

Children’s Hospital revives plan for pedestrian bridge

YouTube cracks down on misinformation on cancer treatment

Doctor of U.S. President Joe Biden says he is fit for duty

BMS, looking to build heart drug business, turns to AI for diagnosis

focus

focus

focus

knowledge